News Author: Jennifer Smith Publish date: October 21, 2019
NEW ORLEANS – Data from the ProAir Digihaler showed that patients with previous, but not current, exacerbations used their inhalers daily.
News Author: Jennifer Smith Publish date: October 21, 2019
NEW ORLEANS – Physicians and patients overestimated asthma control in an observational study.
News Author: Jennifer Smith Publish date: October 9, 2019
Overall survival rates were similar with different treatment approaches, including watchful waiting.
News Author: Jennifer Smith Publish date: October 8, 2019
The median duration of response exceeded 2 years with acalabrutinib monotherapy.
News Author: Jennifer Smith Publish date: October 8, 2019
SAN FRANCISCO – Dr. Yvonne A. Efebera and Dr. Nina Shah debate whether patients with multiple myeloma should receive maintenance until progression....
News Author: Jennifer Smith Publish date: October 7, 2019
A trio of physician scientists have won the Nobel Prize for their work, which has implications for the treatment of anemia, cancer, and other disea...
Article Author: Jennifer Smith Publish date: October 7, 2019
Cleveland Clinic has a new chair of its hematology/medical oncology department, and researchers have won grants to study melanoma, head and neck ca...
News Author: Jennifer Smith Publish date: October 3, 2019
As of Oct. 1, there have been 1,080 confirmed and probable cases of lung injury associated with the use of e-cigarettes, or vaping.
News Author: Jennifer Smith Publish date: October 3, 2019
SAN FRANCISCO – Experts debate the role of chemoimmunotherapy as first-line treatment of chronic lymphocytic leukemia.
News Author: Jennifer Smith Publish date: October 1, 2019
SAN FRANCISCO – Regulators must consider several factors when expanding the use of an approved biosimilar from one indication to another, based on ...
News Author: Jennifer Smith Publish date: October 1, 2019
BOSTON – Reasons for treatment discontinuation varied by regimen and line of therapy.
News Author: Jennifer Smith Publish date: October 1, 2019
SAN FRANCISCO – Researchers are testing blinatumomab and inotuzumab ozogamicin as first-line treatment in B-cell acute lymphoblastic leukemia.
News Author: Jennifer Smith Publish date: September 27, 2019
BOSTON – None of the patients in the trial developed grade 3 or higher cytokine-release syndrome.
News Author: Jennifer Smith Publish date: September 26, 2019
BOSTON – Response rates observed with subcutaneous daratumumab–based combinations in the PLEIADES trial were similar to rates observed with intrave...
News Author: Jennifer Smith Publish date: September 26, 2019
BOSTON – Carfilzomib plus cyclophosphamide, lenalidomide, and dexamethasone significantly prolonged progression-free survival, compared with two ot...
